Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression
| Autor: | William Oh, Uma Chippada-Venkata, Yixuan Gong |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty MMP Angiogenesis Matrix metalloproteinase inhibitor business.industry Cancer Review Matrix metalloproteinase Tissue inhibitor of metalloproteinase medicine.disease prostate cancer lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lcsh:RC254-282 Metastasis Extracellular matrix Prostate cancer Oncology medicine Cancer research TIMP business |
| Zdroj: | Cancers, Vol 6, Iss 3, Pp 1298-1327 (2014) Cancers |
| ISSN: | 2072-6694 |
| Popis: | Matrix metalloproteinases (MMPs), a group of zinc-dependent endopeptidases involved in the degradation of the extracellular matrix, play an important role in tissue remodeling associated with various physiological processes such as morphogenesis, angiogenesis, and tissue repair, as well as pathological processes including cirrhosis, arthritis and cancer. The MMPs are well established as mediators of tumor invasion and metastasis by breaking down connective tissue barriers. Although there has been a vast amount of literature on the role of MMPs in invasion, metastasis and angiogenesis of various cancers, the role of these endopeptidases in prostate cancer progression has not been systematically reviewed. This overview summarizes findings on the tissue and blood expression of MMPs, their function, regulation and prognostic implication in human prostate cancer, with a focus on MMP-2, -7, -9, MT1-MMP and tissue inhibitor of metalloproteinase 1 (TIMP-1). This review also summarizes the efficacy and failure of early-generation matrix metalloproteinase inhibitors (MMPIs) in the treatment of metastatic prostate cancer and highlights the lessons and challenges for next generation MMPIs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|